Want to see IN:THEMISMED full AI Analyst Report?
Themis Medicare Limited (THEMISMED) AI Stock Analysis
Top Page
Themis Medicare Limited
(NSE:THEMISMED)
The score is primarily constrained by the latest deterioration in profitability and cash generation. Broad technical weakness reinforces the risk, while the balance sheet offers some support and the valuation is only moderately attractive. Oversold momentum indicators provide potential recovery support but not enough evidence to offset the fundamental pressure.
Themis Medicare Limited (THEMISMED) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 8.73B
- Dividend Yield
- 0.53%
- Average Volume (3M)
- 17.67K
- Price to Earnings (P/E)
- 21.9
- Beta (1Y)
- 1.36
- Revenue Growth
- -12.75%
- EPS Growth
- ―
- Country
- India
- Employees
- 1,509
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
Themis Medicare Limited Business Overview & Revenue Model
Company Description
Themis Medicare Limited, along with its affiliated entities, is a pharmaceutical company that produces and supplies medicinal goods for both the Indian and international markets. Its product portfolio encompasses active pharmaceutical ingredients (AP...
How the Company Makes Money
Themis Medicare Limited primarily makes money by manufacturing and selling pharmaceutical products, with revenue recognized from the sale of finished formulations and/or pharma-related products to customers such as distributors, hospitals, pharmacies...
Themis Medicare Limited Financial Statement Overview
Summary
Historically profitable with a relatively solid balance sheet, but the latest period shows a sharp collapse in margins, operating losses, negative operating cash flow, and negative free cash flow. The income statement and cash-flow weakness outweigh the company's manageable leverage and sizeable equity base.
Income Statement
40NegativeBalance Sheet
72PositiveCash Flow
35Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.33B | 3.42B | 4.06B | 3.82B | 3.54B | 3.95B |
| Gross Profit | 1.49B | 1.09B | 2.74B | 2.42B | 2.36B | 2.43B |
| EBITDA | -253.80M | 229.38M | 490.48M | 733.17M | 789.56M | 1.02B |
| Net Income | 399.75M | 11.44M | 298.33M | 435.24M | 569.01M | 728.81M |
Balance Sheet | ||||||
| Total Assets | 0 | 5.98B | 5.88B | 5.66B | 5.14B | 4.28B |
| Cash, Cash Equivalents and Short-Term Investments | 91.50M | 91.50M | 65.59M | 99.22M | 125.47M | 202.79M |
| Total Debt | 0 | 1.00B | 829.88M | 957.92M | 923.75M | 797.32M |
| Total Liabilities | -3.99B | 1.99B | 1.85B | 1.89B | 1.75B | 1.40B |
| Stockholders Equity | 3.99B | 3.99B | 4.03B | 3.78B | 3.39B | 2.87B |
Cash Flow | ||||||
| Free Cash Flow | -40.38M | -167.31M | 192.84M | 36.76M | -126.55M | 137.67M |
| Operating Cash Flow | -14.84M | -118.60M | 347.10M | 220.94M | 160.93M | 343.94M |
| Investing Cash Flow | -6.82M | -45.09M | -121.74M | -159.48M | -239.62M | -155.86M |
| Financing Cash Flow | 37.41M | 126.83M | -258.98M | -87.70M | 1.36M | -175.47M |
Themis Medicare Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:THEMISMED, the sentiment is Negative. The current price of 95.00 is below the 20-day moving average (MA) of 103.42, below the 50-day MA of 114.14, and below the 200-day MA of 100.44, indicating a bearish trend. The MACD of -5.88 indicates Positive momentum. The RSI at 34.50 is Neutral, neither overbought nor oversold. The STOCH value of 41.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:THEMISMED.
Themis Medicare Limited Peers Comparison
Overall Rating
IN:JAGSNPHARM78Outperform
IN:VENUSREM69Neutral
IN:ZIMLAB60Neutral
IN:WANBURY56Neutral
IN:INDSWFTLAB51Neutral- IN:THEMISMED48Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| IN:JAGSNPHARM | 78Outperform | INR 14.33B | 31.87 | ― | 1.84% | 11.71% | -26.92% |
| IN:VENUSREM | 69Neutral | INR 16.46B | 13.61 | ― | 0.82% | 20.22% | 73.03% |
| IN:ZIMLAB | 60Neutral | INR 7.32B | 166.21 | ― | ― | 7.55% | -57.19% |
| IN:WANBURY | 56Neutral | INR 6.63B | 10.94 | ― | ― | 3.63% | 24.22% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| IN:INDSWFTLAB | 51Neutral | INR 31.95B | 53.99 | ― | ― | 66.39% | -72.31% |
| IN:THEMISMED | 48Neutral | INR 8.75B | 21.85 | ― | 0.53% | -12.75% | ― |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:THEMISMED | Themis Medicare Limited | 95.00 | -29.64 | -23.78% | |
| IN:INDSWFTLAB | Ind-Swift Laboratories Ltd. | 367.40 | 265.25 | 259.67% | |
| IN:JAGSNPHARM | Jagsonpal Pharmaceuticals Ltd. | 216.90 | -5.32 | -2.40% | |
| IN:VENUSREM | Venus Remedies Limited | 1231.75 | 791.09 | 179.52% | |
| IN:WANBURY | Wanbury Limited | 189.75 | -73.75 | -27.99% | |
| IN:ZIMLAB | Zim Laboratories Ltd. | 136.45 | 63.40 | 86.79% |
Themis Medicare Limited Corporate Events
Themis Medicare Seeks Shareholder Nod to Extend Independent Director’s Term
Themis Medicare Limited has initiated a governance process to secure shareholder approval for the re-appointment of independent director Mr. Bhaskar Vemban Iyer. His first term ends on 11 November 2026, and the board, acting on the Nomination and Rem...
Themis Medicare Resolutions Cleared at 56th AGM with Requisite Majority
Themis Medicare Limited has reported that all resolutions proposed at its 56th Annual General Meeting, held on 30 September 2026, were approved by shareholders with the requisite majority. The company has provided the scrutinizer’s report and d...
Themis Medicare Says No Undisclosed News Behind Share Volume Surge
Themis Medicare Limited has responded to queries from BSE and NSE after a significant increase in trading volume in its shares. The exchanges sought clarification to ensure investors had current and relevant information and to safeguard market integr...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 23, 2026